发布求助
文献互助 智能选刊 最新文献

Journal of the Society for Integrative Oncology最新文献

筛选
英文 中文
Nerium oleander (Oleandrin). 夹竹桃。
Journal of the Society for Integrative Oncology Pub Date : 2007-01-01
{"title":"Nerium oleander (Oleandrin).","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":87409,"journal":{"name":"Journal of the Society for Integrative Oncology","volume":"5 1","pages":"43-4"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26561056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Discussing complementary therapies in an oncology setting. 讨论肿瘤学背景下的补充疗法。
Journal of the Society for Integrative Oncology Pub Date : 2007-01-01 DOI: 10.2310/7200.2006.028
Lorenzo Cohen, Michael H Cohen, Catherine Kirkwood, Nancy C Russell
{"title":"Discussing complementary therapies in an oncology setting.","authors":"Lorenzo Cohen, Michael H Cohen, Catherine Kirkwood, Nancy C Russell","doi":"10.2310/7200.2006.028","DOIUrl":"https://doi.org/10.2310/7200.2006.028","url":null,"abstract":"When herbal or other biologic therapies are used with conventional treatments, adverse drug-herb interactions can occur. Of course, benefits can also be derived that decrease the side effects of conventional medicine and/or support general recovery, a sense of well-being, and health. Even though people with cancer typically use complementary medicines along with conventional treatment, many of them do so without informing anyone on their health care team. This lack of discussion is of grave concern, especially for ingestible substances. This article considers some of the barriers to open communication about complementary treatments and provides support for why it is the health care professional's responsibility to bring up the topic for both medical and legal reasons. Strategies for initiating and guiding an informed dialogue are described and important resources are provided.","PeriodicalId":87409,"journal":{"name":"Journal of the Society for Integrative Oncology","volume":"5 1","pages":"18-24"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26561053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 27
Reduction of lymphedema using complete decongestive therapy: roles of prior radiation therapy and extent of axillary dissection. 使用完全减充血疗法减少淋巴水肿:先前放射治疗的作用和腋窝清扫的程度。
Journal of the Society for Integrative Oncology Pub Date : 2007-01-01 DOI: 10.2310/7200.2007.004
R Croft Thomas, Kennedy Hawkins, Stephanie H Kirkpatrick, Tammy E Mondry, Sheryl Gabram-Mendola, Peter A S Johnstone
{"title":"Reduction of lymphedema using complete decongestive therapy: roles of prior radiation therapy and extent of axillary dissection.","authors":"R Croft Thomas,&nbsp;Kennedy Hawkins,&nbsp;Stephanie H Kirkpatrick,&nbsp;Tammy E Mondry,&nbsp;Sheryl Gabram-Mendola,&nbsp;Peter A S Johnstone","doi":"10.2310/7200.2007.004","DOIUrl":"https://doi.org/10.2310/7200.2007.004","url":null,"abstract":"<p><p>Although radiation therapy (RT) contributes to lymphedema (LE), it is unknown whether RT contributes to more difficulty (more treatments) or less success (decreased LE reduction) with therapy for established LE. We reviewed the results of complete decongestive therapy (CDT) for LE with respect to a history of RT and the number of lymph nodes dissected. Breast cancer survivors with LE were referred to CDT-certified therapists. CDT consists of treatment (phase 1) and maintenance (phase 2) phases. During phase 1, the patient meets with a therapist daily until the LE reduction plateaus; then phase 2 (self-care) begins. During phase 1, LE is quantified weekly at a minimum. Fifty-three patients underwent CDT and completed phase 1. The median number of treatments to plateau was 12 (range 6-25); the median limb volume reduction was 36% (-4-119%). Thirty-six patients with an RT history had an insignificant difference in LE reduction (p = .49) and the number of sessions to plateau (p = .54) compared with 17 patients without RT. The median examined number of nodes was 12 (range 3-28). No significant correlation was observed between the number of nodes examined and percent reduction (r = -.390); no significant correlation (r = .291; critical r = .396 for p = .05 for both cases) was observed between the number of nodes sampled and the number of sessions to plateau. Patients with LE obtained relief regardless of whether they received surgery or surgery plus RT. The insignificant correlation between the number of lymph nodes and percent reduction could become significant with a larger sample size.</p>","PeriodicalId":87409,"journal":{"name":"Journal of the Society for Integrative Oncology","volume":"5 3","pages":"87-91"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26944059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 16
Flax and flaxseed oil (Linum usitatissimum): a review by the Natural Standard Research Collaboration. 亚麻和亚麻籽油(Linum usitatissimum):自然标准研究合作的综述。
Journal of the Society for Integrative Oncology Pub Date : 2007-01-01 DOI: 10.2310/7200.2007.005
Ethan Basch, Steve Bent, Jeffrey Collins, Cynthia Dacey, Paul Hammerness, Michelle Harrison, Michael Smith, Philippe Szapary, Catherine Ulbricht, Mamta Vora, Wendy Weissner
{"title":"Flax and flaxseed oil (Linum usitatissimum): a review by the Natural Standard Research Collaboration.","authors":"Ethan Basch,&nbsp;Steve Bent,&nbsp;Jeffrey Collins,&nbsp;Cynthia Dacey,&nbsp;Paul Hammerness,&nbsp;Michelle Harrison,&nbsp;Michael Smith,&nbsp;Philippe Szapary,&nbsp;Catherine Ulbricht,&nbsp;Mamta Vora,&nbsp;Wendy Weissner","doi":"10.2310/7200.2007.005","DOIUrl":"https://doi.org/10.2310/7200.2007.005","url":null,"abstract":"<p><p>The objective of this study was to evaluate the scientific evidence on flaxseed, including expert opinion, folkloric precedent, history, pharmacology, kinetics/dynamics, interactions, adverse effects, toxicology, and dosing. Electronic searches were conducted in 9 databases, 20 additional journals (not indexed in common databases), and bibliographies from 50 selected secondary references. No restrictions were placed on the language or quality of the publications. All literature collected pertained to efficacy in humans, dosing, precautions, adverse effects, use in pregnancy/lactation, interactions, alteration of laboratory assays, and mechanisms of action. Standardized inclusion/exclusion criteria are used for selection. Grades were assigned using an evidence-based grading rationale. A review of the literature on flaxseed yielded 13 categories for which flaxseed had been studied in humans, including constipation/laxative, attention-deficit hyperactivity disorder, hyperlipidemia, atherosclerosis/coronary artery disease, breast cancer, cyclic mastalgia (breast pain), menopausal symptoms, hyperglycemia/diabetes, hypertension, lupus nephritis, human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS), and prostate cancer. Most of the available evidence investigates the efficacy of alpha-linoleic acid found in flaxseed compared with fish oil, and almost all of the available studies are poor quality. Although flaxseed and flaxseed oil have several promising future uses, the available literature does not support recommendation for any condition at this time.</p>","PeriodicalId":87409,"journal":{"name":"Journal of the Society for Integrative Oncology","volume":"5 3","pages":"92-105"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26947708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 70
Integrative Oncology Practice Guidelines. 综合肿瘤学实践指南。
Journal of the Society for Integrative Oncology Pub Date : 2007-01-01
Gary E Deng, Barrie R Cassileth, Lorenzo Cohen, Jyothirmai Gubili, Peter A S Johnstone, Nagi Kumar, Andrew Vickers, Donald Abrams, David Rosenthal, Stephen Sagar, Debu Tripathy
{"title":"Integrative Oncology Practice Guidelines.","authors":"Gary E Deng,&nbsp;Barrie R Cassileth,&nbsp;Lorenzo Cohen,&nbsp;Jyothirmai Gubili,&nbsp;Peter A S Johnstone,&nbsp;Nagi Kumar,&nbsp;Andrew Vickers,&nbsp;Donald Abrams,&nbsp;David Rosenthal,&nbsp;Stephen Sagar,&nbsp;Debu Tripathy","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":87409,"journal":{"name":"Journal of the Society for Integrative Oncology","volume":"5 2","pages":"65-84"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26731354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
How to improve accrual to clinical trials of symptom control 2: design issues. 如何提高症状控制临床试验的应计性2：设计问题。
Journal of the Society for Integrative Oncology Pub Date : 2007-01-01 DOI: 10.2310/7200.2007.001
Andrew J Vickers
{"title":"How to improve accrual to clinical trials of symptom control 2: design issues.","authors":"Andrew J Vickers","doi":"10.2310/7200.2007.001","DOIUrl":"10.2310/7200.2007.001","url":null,"abstract":"<p><p>The major reason that clinical trials in integrative oncology fail is that inadequate numbers of patients are accrued. One important cause of inadequate accrual is eligibility criteria that are overly restrictive. Investigators should critically examine every single inclusion or exclusion criterion to determine whether possible benefits to the study clearly outweigh harms in terms of reduced accrual. Accrual will also be harmed if the burdens for participation--traveling to appointments, completing questionnaires--are excessive compared with the benefits for patients. In a traditional randomized trial, half of participants do not receive treatment, reducing the benefits expected by any patient. This can be offset by guaranteeing free treatment to patients in the control group after they have completed the study. Patient burden can be reduced by limiting the number of hospital visits and avoiding excessive numbers of questionnaires.</p>","PeriodicalId":87409,"journal":{"name":"Journal of the Society for Integrative Oncology","volume":"5 2","pages":"61-4"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2597108/pdf/nihms80437.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26731353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
How to improve accrual to clinical trials of symptom control 1: recruitment strategies. 如何提高症状控制临床试验的收益1：招募策略。
Journal of the Society for Integrative Oncology Pub Date : 2007-01-01 DOI: 10.2310/7200.2006.034
Andrew J Vickers
{"title":"How to improve accrual to clinical trials of symptom control 1: recruitment strategies.","authors":"Andrew J Vickers","doi":"10.2310/7200.2006.034","DOIUrl":"10.2310/7200.2006.034","url":null,"abstract":"<p><p>Inadequate patient accrual remains the primary problem for clinical trials of integrative therapies for symptom control. Many difficulties can be predicted and avoided if a careful, evidence-based approach to trial design is taken: trialists should attempt to get as many data as possible on the study population by querying institutional databases, examining case notes, following inpatient rounds, and conducting \"dry runs\" by asking doctors for referrals. Trials require aggressive recruitment strategies, including advertising, writing to patients at home, scanning clinic lists, and identifying critical points during clinical care at which patients can be approached. The information given to patients during any initial contact should be as simple and general as possible: presenting too much information too soon can be overwhelming and off-putting.</p>","PeriodicalId":87409,"journal":{"name":"Journal of the Society for Integrative Oncology","volume":"5 1","pages":"38-42"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2596475/pdf/nihms80427.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26561055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Justification for separate consideration of two broad categories of cancer patient use of complementary medicine. 单独考虑两大类癌症患者使用补充医学的理由。
Journal of the Society for Integrative Oncology Pub Date : 2007-01-01 DOI: 10.2310/7200.2006.030
Maurie Markman
{"title":"Justification for separate consideration of two broad categories of cancer patient use of complementary medicine.","authors":"Maurie Markman","doi":"10.2310/7200.2006.030","DOIUrl":"https://doi.org/10.2310/7200.2006.030","url":null,"abstract":"<p><p>A strong argument can be made in support of the concept that individual cancer patient use of complementary medicine can be divided into two broad categories. This article provides the rationale for this statement and the potential utility of this approach.</p>","PeriodicalId":87409,"journal":{"name":"Journal of the Society for Integrative Oncology","volume":"5 2","pages":"50-2"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26731349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aloe vera (Aloe barbadensis, Aloe capensis). 芦荟（芦荟、山柑芦荟）。
Journal of the Society for Integrative Oncology Pub Date : 2007-01-01
{"title":"Aloe vera (Aloe barbadensis, Aloe capensis).","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":87409,"journal":{"name":"Journal of the Society for Integrative Oncology","volume":"5 2","pages":"85"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26731355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Introduction to the massage therapy section. 介绍按摩疗法部分。
Journal of the Society for Integrative Oncology Pub Date : 2007-01-01 DOI: 10.2310/7200.2007.016
Cynthia Myers
{"title":"Introduction to the massage therapy section.","authors":"Cynthia Myers","doi":"10.2310/7200.2007.016","DOIUrl":"https://doi.org/10.2310/7200.2007.016","url":null,"abstract":"","PeriodicalId":87409,"journal":{"name":"Journal of the Society for Integrative Oncology","volume":"5 4","pages":"132"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2310/7200.2007.016","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27904833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信